Parkinson’s Disease Treatment Market
Global Parkinson’s Disease Treatment Market Size, Share & Trends Analysis Report by Type ((Drugs (Dopamine Receptor Agonists, MAO-Inhibitors, Carbidopa-Levodopa, Catechol O-methyltransferase (COMT) Inhibitors, Anticholinergics, and Others) and Surgical Procedures (Deep Brain Stimulation, Vagus Nerve Stimulation, and Others), Forecast 2019-2025 Update Available - Forecast 2024-2030
The global Parkinson’s disease treatment market is expected to grow at a CAGR of over 6% during the forecast period. The factors that drive the growth of the market include the increased prevalence of Parkinson’s disease across the globe. As per the Institute for Health Metrics and Evaluation in 2019, around 10 million people suffered from Parkinson’s disease globally. Every year more than a million incidences of Parkinson’s disease are registered globally, which is expected to drive the global Parkinson’s disease treatment market in the near future.
Rising geriatric population is one of the major factors that is expected to surge the market growth during the forecast period. The elderly population is at increased risk of developing Parkinson's disease, which in turn creates scope for the growth of the Parkinson’s disease treatment market during the forecast period. However, lack of awareness and poor reimbursement policies in several developing economies is anticipated to hinder the growth of the market during the forecast period.Besides, several R&D activities concerning the development of the novel drugs will create ample opportunities for market growth in the near future.
Segmental Outlook
The global Parkinson’s disease treatment market is segmented on the basis of type into drug and surgical procedures. Based on the drug class, the market is segmented into dopamine receptor agonists, MAO-inhibitors, carbidopa-levodopa, catechol o-methyltransferase (COMT) inhibitors, anticholinergics, and others. The other segment further includes amantadine and selegiline. Based on the surgical procedures, the market is segmented into deep brain stimulation, vagus nerve stimulation, and others that include pallidotomy and thalamotomy.
Global Parkinson’s Disease Treatment Market by Surgical Procedures,2018 (%)
Deep Brain Stimulators Segment to Hold a Significant Share
Amongst the surgical procedures segment of the market, deep brain stimulators segment is estimated to hold the most significant share in the market. Patients with moderate disabilities from Parkinson’s disease can opt for surgical procedures. Deep brain stimulators are used for controlling and lessening the symptoms of Parkinson's disease. The segmental growth is accredited to the rising incidence of Parkinson’s disease. Several novel product launches have been observed significantly in the market, for instance, in January 2019, Boston Scientific Corp. launched two deep brain stimulation systems including Vercise Gevia and non-rechargeable Vercise Primary Cell systems. Thus, this is expected to drive the segmental market growth.
Regional Outlook
The global Parkinson’s disease treatment market is geographically segmented as North America, Europe, Asia-Pacific and Rest of the World. The North American region is estimated to hold a prominent share in the global market. The regional growth is attributed to the increasing incidences of Parkinson’s diseases in the region. According to the report of Parkinson’s Canada, Parkinson’s disease affects 1 in every 500 people in Canada. In 2018, over 100,000 Canadians were living with Parkinson’s and around 6,600 new cases of Parkinson’s disease are estimated to be diagnosed each year in Canada (based on the annual incidence of 20 new cases per 100,000 people). Therefore, the utility of DBS for the treatment of Parkinson’s disease coupled with a large customer base in Canada is projected to drive the growth of the market in Canada. Further, the US contributes significantly to the market due to huge expenditure on healthcare by the government and the adoption of innovative technologies in the healthcare domain.
Global Parkinson’s Disease Treatment Market, by Region 2018 (%)
Market Players Outlook
Some of the prominent players operating in the global Parkinson’s diseases treatment market include Medtronic Plc, AbbVie Inc., Boehringer Ingelheim GmbH, GlaxoSmithKline Plc, Boston Scientific Corp., Cipla Inc., Mylan NV, Novartis International AG, Eli Lilly& Co., Pfizer Inc., and Teva Pharmaceutical Industries Ltd.among others. These manufacturers are adopting various strategies such as new product launches and approvals, merger and acquisition, partnerships and collaborations, and many others to thrive in a competitive environment.
For instance, since May 2018, after the preclinical studies by Eli Lilly, it declared that enhancing dopamine receptor D1 aids in improving cognitive function.Eli Lilly is engaged in the development of LY3154207. The novel drug is an orally administered enhancer of dopamine receptor D1, which is a sort of dopamine receptor involved in cognition for the treatment of Parkinson’s disease. In addition, in October 2019, the US FDA approved a novel drug Nourianz (istradefylline) for Parkinson’s “Off” time manufactured by Kyowa KirinInc.
The Report Covers
- Market value data analysis of 2018 and forecast to 2025.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Parkinson’s disease treatment market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Key Strategy Analysis
3.2. Key Company Analysis
3.2.1. Medtronic Plc
3.2.1.1. Overview
3.2.1.2. Financial Analysis
3.2.1.3. SWOT Analysis
3.2.1.4. Recent Developments
3.2.2. AbbVie Inc.
3.2.2.1. Overview
3.2.2.2. Financial Analysis
3.2.2.3. SWOT Analysis
3.2.2.4. Recent Developments
3.2.3. Boston Scientific Corp.
3.2.3.1. Overview
3.2.3.2. Financial Analysis
3.2.3.3. SWOT Analysis
3.2.3.4. Recent Developments
3.2.4. Boehringer Ingelheim GmbH
3.2.4.1. Overview
3.2.4.2. Financial Analysis
3.2.4.3. SWOT Analysis
3.2.4.4. Recent Developments
3.2.5. GlaxoSmithKline Plc
3.2.5.1. Overview
3.2.5.2. Financial Analysis
3.2.5.3. SWOT Analysis
3.2.5.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Parkinson’s Disease Treatment Market by Type
5.1.1. Drugs
5.1.1.1. Dopamine Receptor Agonists
5.1.1.2. MAO-Inhibitors
5.1.1.3. Carbidopa-Levodopa
5.1.1.4. Catechol O-methyltransferase (COMT) Inhibitors
5.1.1.5. Anticholinergics
5.1.1.6. Others(Amantadine, Selegiline)
5.1.2. Surgical Procedures
5.1.2.1. Deep Brain Stimulation
5.1.2.2. Vagus Nerve Stimulation
5.1.2.3. Others (Pallidotomy, Thalamotomy)
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Abbott Laboratories Inc.
7.2. ACADIA Pharmaceuticals Inc.
7.3. Aleva Neurotherapeutics SA
7.4. Axovant Gene Therapies Ltd.
7.5. Boehringer Ingelheim GmbH
7.6. Boston Scientific Corp.
7.7. Cipla Inc.
7.8. Daiichi Sankyo Co. Ltd.
7.9. Eli Lilly & Co.
7.10. GlaxoSmithKline Plc
7.11. Medtronic Plc
7.12. Mylan NV
7.13. NeuroPace, Inc.
7.14. Novartis International AG
7.15. Nuvectra Corp.
7.16. Orion Corp.
7.17. Pfizer Inc.
7.18. Renishaw PLC
7.19. Teva Pharmaceutical Industries Ltd.
7.20. UCB S.A.
7.21. Vertical Pharmaceuticals, LLC
1. GLOBAL PARKINSON’S DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
2. GLOBAL PARKINSON’S DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
3. GLOBAL DOPAMINE RECEPTOR AGONISTS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
4. GLOBAL MAO-INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
5. GLOBAL CARBIDOPA-LEVODOPA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
6. GLOBAL CATECHOL O-METHYLTRANSFERASE (COMT) INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
7. GLOBAL ANTICHOLINERGICS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
8. GLOBAL OTHER PARKINSON’S DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
9. GLOBAL PARKINSON’S DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY SURGICAL PROCEDURES, 2018-2025 ($ MILLION)
10. GLOBAL DEEP BRAIN STIMULATION MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
11. GLOBAL VAGUS NERVE STIMULATION MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
12. GLOBAL OTHER SURGICAL PROCEDURES FOR PARKINSON’S DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
13. GLOBAL PARKINSON’S DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
14. NORTH AMERICAN PARKINSON’S DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
15. NORTH AMERICAN PARKINSON’S DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
16. EUROPEAN PARKINSON’S DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
17. EUROPEAN PARKINSON’S DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
18. ASIA-PACIFIC PARKINSON’S DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
19. ASIA-PACIFIC PARKINSON’S DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
20. REST OF THE WORLD PARKINSON’S DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
1. GLOBAL PARKINSON’S DISEASE TREATMENT MARKET SHARE BY TYPE, 2018 VS 2025 (%)
2. GLOBAL PARKINSON’S DISEASE TREATMENT MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
3. US PARKINSON’S DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
4. CANADA PARKINSON’S DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
5. UK PARKINSON’S DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
6. FRANCE PARKINSON’S DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
7. GERMANY PARKINSON’S DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
8. ITALY PARKINSON’S DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
9. SPAIN PARKINSON’S DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
10. ROE PARKINSON’S DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
11. INDIA PARKINSON’S DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
12. CHINA PARKINSON’S DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
13. JAPAN PARKINSON’S DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
14. REST OF ASIA-PACIFIC PARKINSON’S DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
15. REST OF THE WORLD PARKINSON’S DISEASE TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
